Thursday May 28, 2026 — Field Note
A deeper look at one story shaping medical device and health tech.
FIELD NOTE
One FDA Approval, Four Advantages at Once: What Guardant's New Liquid Biopsy Signals for Diagnostics.
While the medtech industry’s attention this month has been on robotics launches, the IVL share fight, and a thinning FDA, a quieter milestone landed on May 20: the FDA approved a new version of Guardant Health’s Guardant360 Liquid CDx, and the stock jumped roughly 25% the same week. For a company whose core product is a blood test, a quarter of its market value moved on a label change. The market saw something structural.
Here is what the label actually says. The new assay reads a genomic footprint 100 times wider than the test it replaces — Guardant calls it the largest FDA-approved liquid biopsy panel. The seven companion diagnostic indications already cleared for the prior Guardant360 CDx carry over to the new test without re-filing. Results come back in as little as seven days. And it ships covered: Guardant says Medicare and commercial payers representing more than 300 million lives already reimburse it.
But the number that moved the stock isn’t the gene count. Guardant360 Liquid CDx is, by the company’s account, the first FDA-approved liquid biopsy to combine genomic and epigenomic profiling from a single blood draw — reading not just which mutations a tumor carries, but how its genes are switched on and off. Guardant reports a several-fold jump in sensitivity for detecting circulating tumor DNA over the prior test, and says the paired signal flags clinically actionable findings that sequencing alone would miss. Independent trade coverage of the approval described it in the same terms.
Set that against the competition. Roche’s FoundationOne Liquid CDx, the incumbent, analyzes more than 300 genes and has built its position on panel breadth and companion-diagnostic depth; Tempus won FDA clearance for its xT CDx on a similarly expansive panel. For most of the last five years, the blood-based profiling fight has been an arms race over how many genes a test could read from a tube of blood. Guardant just reframed the contest. The pitch is no longer “more genes” but “more kinds of data” — genotype plus a phenotype-adjacent layer the others don’t report. Whether epigenomic integration proves clinically decisive across tumor types is unproven, and Guardant’s broader phenotype reporting is offered as a professional service the company notes the FDA has not reviewed. What is no longer theoretical is that a regulator has now cleared an assay built on the multiomic premise.
The way Guardant got it cleared is its own lesson. The company did not file a new test from zero and argue each cancer indication over again; it brought a more capable assay through the FDA and let the prior approved claims transfer. Then it put its entire portfolio on one AI-enabled foundation it calls the Smart Platform — the same architecture now underpinning tests for early screening, recurrence monitoring, and treatment selection. One cleared core, many products hanging off it. A company that spent years and millions clearing each device as a standalone fight is looking at a different playbook.
The stakes scale with the category. The U.S. liquid biopsy market sat at roughly $2.8 billion in 2026 and is forecast to approach $8.9 billion by 2035, and it is crowded — diagnostics incumbents on one side, data-first entrants like Tempus on the other. What makes this approval stand out in that field is that it bundles four advantages a competitor would normally have to win one at a time. The first is a differentiated technical claim: the multiomic read, not just a bigger panel. The second is regulatory leverage: seven approved indications that rode forward into the new assay instead of being re-litigated. The third is reimbursement, already in place across more than 300 million covered lives before the test goes to market. The fourth is platform reach: one cleared core spreading across an entire product line. Any one of those is an edge. Assembled at once, they are a moat.
For device and diagnostics teams watching from adjacent categories, the signal travels. The basis of competition in comprehensive genomic profiling is shifting from panel size to data integration. Regulatory pathways that let approved claims ride forward into a successor assay are worth designing for from the start. And the gap between a cleared test and a commercial one increasingly comes down to whether reimbursement and platform leverage were built in before the FDA ever said yes.
SPONSORED BY RŌG HEALTH
Most medical device companies don't fail on technology. They fail on sequencing.
The most expensive mistakes in Class II and III device commercialization aren’t made in the field. They’re made before it — launching before buyer clarity exists, fundraising before the story holds up, hiring before positioning is right.
The CLIF Analysis from RŌG Health is a quick, structured external diagnostic that helps you identify gaps before they become costly. One week. Built for medical device and medtech teams.
Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.